Article Contents ::
- 1 Details About Generic Salt :: Tiludron
- 2 Main Medicine Class:: Hormone,biphosphonates
- 3 (tie-LOO-droe-nate) Skelid Class: Hormone/biphosphonates
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Tiludron
Main Medicine Class:: Hormone,biphosphonates
(tie-LOO-droe-nate)
Skelid
Class: Hormone/biphosphonates
Drugs Class ::
Action Inhibits normal and abnormal bone resorption.
Indications for Drugs ::
Indications Treatment of Paget’s disease of bone.
Drug Dose ::
Route/Dosage
ADULTS: PO 400 mg qd for 3 months.
Contraindication ::
Contraindications Standard considerations.
Drug Precautions ::
Precautions
Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Renal function impairment: Not recommended in patients with CrCl < 30 ml/min.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: Hypertension; syncope. CNS: Paresthesia; vertigo; somnolence; anxiety; nervousness; insomnia; involuntary muscle contractions. DERM: Rash; pruritis; sweating. GI: Diarrhea; nausea; constipation; vomiting; flatulence; abdominal pain; norexia; dry mouth; gastritis. META: Hyperparathyroidism. EENT: Cataract; conjunctivitis; glaucoma; rhinitis; sinusitis; pharyngitis. OTHER: Fatigue; asthenia; chest pain; edema; arthrosis; flushing.
Drug Mode of Action ::
Action Inhibits normal and abnormal bone resorption.
Drug Interactions ::
Interactions
Aspirin, calcium, aluminum- or magnesium-containing antacids: Decrease tiludronate bioavailability. Indomethacin: Increases tiludronate bioavailability.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Note any hypersensitivity to biphosphonates and evidence of renal function impairment.
- Record dates of any previous treatment with tiludronate.
- Monitor patient for side effects.
|
Drug Storage/Management ::
Administration/Storage
- Have patient take drug on empty stomach 2 hr before or after meals.
- Swallow tablet with 6–8 oz of plain water. Do not use beverages other than plain water (eg, mineral water).
- Calcium or mineral supplements should be taken at least 2 hours before or after tiludronate.
- Aluminum or magnesium-containing antacids, if needed, should be taken at least 2 hr after taking tiludronate.
- Administer aspirin or indomethacin, if ordered, either 2 hr before or after tiludronate.
- The 3 month course of treatment may be repeated in some patients following a 3 month tiludronate-free interval.
- Store at controlled room temperature. Do not remove from foil strip until ready for administration.
Drug Notes ::
Patient/Family Education
- Instruct patient to take drug with 6–8 oz of plain water. Advise patient to not use any other beverage (eg, mineral water).
- Instruct patient to avoid eating 2 hr before and 2 hr after taking medication since absorption of drug is reduced by food.
- Instruct patient to maintain adequate intake of vitamin D and calcium.
- Advise patient to take calcium or mineral supplements 2 hr before or 2 hr after tiludronate.
- Advise patient to take aluminum- or magnesium-containing antacids at least 2 hr after tiludronate.
- Advise patients taking aspirin or indomethacin to take these 2 hr before or after tiludronate.
- Advise patient to not remove medication from foil strip until just before administration.